Ergomed Share Discussion Threads

[mirabeau] 16/5/2019 08:07

Doing well now

[ih_433513] 16/5/2019 07:45

Very good trading announcement. Very inspired recent buying too! Pound to a penny that we’ll be having a fund raising shortly to buy more pharmacovigilance companies and maybe fund the Haemostatix Phase 3 trial. If the CVM Multikine trial is a success that would be huge.

[bermudashorts] 09/5/2019 14:13

Thanks mfhmfm

[mfhmfh] 09/5/2019 13:41

Harwood Capital LLP have increased their holding.

[mfhmfh] 25/4/2019 13:25

nice buys coming in today

[bermudashorts] 23/4/2019 06:31

Nice RNS

Ergomed's PrimeVigilance awarded 2019 Queen's Award for Enterprise

[jamtomorrow2] 10/4/2019 00:38

Wonder if they will have to write off Haemostatix? No Phase 3 deal a year after supposedly great Phase 2 results - doesn’t sound good to me. Why don’t they do it themselves? Maybe they will if Multikine turns out to be a winner. It looks like Multikine is the last chance on the partnered drugs. The only other one was the Ferrer drug and like Haemostatix the Phase 2 results were touted as great but clearly they weren’t as no partners have been found to take the drug forward into Phase 3. CROs may be good at conducting trials but they seem to be poor at knowing whether the drugs will be winners.

[mfhmfh] 09/4/2019 14:33

Buys coming in. Let's see what tomorrow brings...

[jamtomorrow2] 06/4/2019 22:08

Interesting that Cel-Sci’s share price has doubled recently on optimism that Multikine’s trial will be successful. Ergomed has an interest in this drug.

[mfhmfh] 31/1/2019 14:41

Slater Investments Ltd above 10%

[mfhmfh] 21/1/2019 08:29

Oryx International Growth Fund above 8%

[mfhmfh] 22/11/2018 14:17

big volume today

[jamtomorrow2] 06/11/2018 15:37

Octopus bailing?

[sicilian_kan] 31/10/2018 16:42

Agreed - thanks for the link

[sidam] 31/10/2018 16:02

They have certainly pushed up thier eps for this and next year.

Looks rather interesting,

[edmonda] 31/10/2018 15:07

Latest note from ED.

[piedro] 18/9/2018 09:13

Interim Results tomorrow

[edmonda] 16/8/2018 08:12

AIM:ERGO - "building for growth"

At the Full Year results, the new CEO Stephen Stamp outlined a value-enhancing vision for the business: a move away from co-development projects towards its existing Clinical Research Services (CRS) and its drug safety and medical information (DS&MI) businesses. Both the CRS and DS&MI businesses have been providing clear, repeatable project revenues and these markets are growing substantially.
However, a number of issues have impacted business performance in the first six months of the year including the delay in the timing of a few key contracts and the lag effect of training up new staff to cope with the influx of expected work over the next few years. The former impacted revenues, the latter weighed on costs.
Our FY2018 and FY2019 estimates have been trimmed to reflect the revised projections. Updating our valuation using peer-based metrics of c1.8x EV/Sales and c18x PE gives a fair value for the Services businesses (CRS and DS&MI) of 215p / share. The Development and Haemostatix businesses add a further 120p to that, based on an NPV (Net Present Value) analysis.

Read the full note here ...

[sharesoc] 01/7/2018 13:58

There is a recent report on Ergomed’s AGM which is available to read in our full member exclusive area here:

[aim_trader] 29/6/2018 12:14

Ergomed to present to investors at the upcoming Proactive One2One Forum on 12th July in London. For details and registration, click here:

[sicilian_kan] 28/6/2018 12:40

In a note to clients, analysts at Numis said that as Ergomed “is constantly hiring ahead of anticipated revenue growth”, a delay in anticipated revenue was going to drive margins lower as utilisation dropped.

They added: “We downgrade our revenues by c.5% to £46.5mln primarily hitting the CRO division (£19.0mln from £21.6mln), with top line growth in PV [PrimeVigilance division] slightly higher, but on a higher cost base (reduced gross margins in both divisions) which effectively delays our EBITDA ramp by one year.”

The broker was, however, fairly ambivalent regarding the delay: “Contract delays are a frequent occurrence in the CRO business, while in the PV division trading seems to have been in line with or slightly ahead of our expectations, while management planned for more.”

roactiveinvestors.co.uk/companies/news/199777/ergomed-revenue-delay-leads-to-numis-downgrade-199777.html

[horndean eagle] 28/6/2018 09:50

It is the companies second profits warning in the last year. Shares are now back to where they were a couple of months ago. I don't think you can complain you have been overly hard done by. The multiple is hardly cheap,